 |
|
|
| |
Combination of an Acetyl CoA Carboxylase Inhibitor With Therapeutics That Promote
Fatty-Acid Oxidation Does Not Improve Antifibrotic Efficacy in a Preclinical NASH Model
|
| |
| |
EASL 2020 Aug 27-29
Reported by Jules Levin
Archana Vijayakumar, Isabel Olson, Ting Wang, David Hollenback, Maria Toteva, James L. Trevaskis, David G. Breckenridge, Jamie Bates - Gilead Sciences, Inc., Foster City, California, USA
References: 1. Abu-Elheiga L, et al. Proc Natl Acad Sci U S A 2005;201:12011-6; 2. Harriman G, et al. Proc Natl Acad Sci U S A 2016;113:E1796-805; 3. Harrison S, et al. J Hepatol 2018;68:S583; 4. Lawitz EJ, et al. Clin Gastroenterol Hepatol 2018;16:1983-91; 5. Loomba R, et al. Gastroenterology 2018;155:1463-73; 6. Mao J, et al. Proc Natl Acad Sci U S A 2006;103:8552-7; 7. Kim CW, et al. Cell Metab 2017;26:576; 8. Bates J, et al. J Hepatol 2020;S0168-8278(20)30281-6; 9. Lally JSV, et al. Cell Metab 2019;29:174-82.e5; 10. Lawitz E, et al. AASLD 2019, poster LP5; 11. Harrison S, et al. J Hepatol. 2018;68:S38; 12. Neuschwander-Tetri BA. Gastroenterol Hepatol 2018;14:582-9.
Acknowledgment: This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
